Monthly growth rates were 83.9% for OZEMPIC, 119.2% for WEGOVY , 84.8% for RYBELSUS, 12.9% for ADLYXIN, 78.8% for TRULICITY, and 254.3% for MOUNJARO
Candidate ASD-associated genes were predicted based on the interaction patterns of known ASD-associated genes
FDA granted full approval to mirvetuximab soravtansine-gynx (Elahere ) for folate-receptor--positive disease after one to three prior lines, significantly prolonging overall and progression-free survival compared with physician-choice chemotherapy [54, 55]
Conclusion: 2026 Evaluation Criteria for GLP-1 Weight-Management Access Novo Nordisk's recent launch of oral Wegovy represents a meaningful development in the GLP-1 weight loss medication market, providing an FDA-approved oral alternative for patients with needle aversion while highlighting the ongoing evolution of format options and pricing structures across this medication category
Data Availability Statement The original contributions presented in this study are included in the article
Early detection and early treatment play an important role in controlling the progression of the disease